We first cleared IL-6 using an IL-6 specific monoclonal antibody (mAb) which led to a diminished tumor control and also a less pronounced immune cell infiltration to the tumor; however, we could not mimic the role of IL-6 by administration of recombinant cytokine. Here, IL6 is linked to neoplasm.